YU46033B - Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata - Google Patents

Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata

Info

Publication number
YU46033B
YU46033B YU205086A YU205086A YU46033B YU 46033 B YU46033 B YU 46033B YU 205086 A YU205086 A YU 205086A YU 205086 A YU205086 A YU 205086A YU 46033 B YU46033 B YU 46033B
Authority
YU
Yugoslavia
Prior art keywords
cyclobutyl
chlorophenyl
dimethyl
henigroscopic
new
Prior art date
Application number
YU205086A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU205086A (en
Inventor
J.E. Jeffery
D. Whybrow
Original Assignee
The Boots Company Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU46033(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Boots Company Plc. filed Critical The Boots Company Plc.
Priority to SI8612050A priority Critical patent/SI8612050A8/sl
Publication of YU205086A publication Critical patent/YU205086A/xx
Publication of YU46033B publication Critical patent/YU46033B/sh
Priority to HRP-2050/86A priority patent/HRP930745B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
YU205086A 1985-12-17 1986-12-02 Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata YU46033B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8612050A SI8612050A8 (sl) 1985-12-17 1986-12-02 Nova nehigroskopična oblika n,n-dimetil-1-1-(4-klorofenil) ciklobutil -3-metilbutilamin klorhidrata
HRP-2050/86A HRP930745B1 (en) 1985-12-17 1993-04-02 New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (2)

Publication Number Publication Date
YU205086A YU205086A (en) 1987-12-31
YU46033B true YU46033B (sh) 1992-12-21

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
YU205086A YU46033B (sh) 1985-12-17 1986-12-02 Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata

Country Status (34)

Country Link
US (2) US4929629A (h)
EP (1) EP0230742B1 (h)
JP (1) JPS62155240A (h)
KR (1) KR940008913B1 (h)
CN (1) CN1016245B (h)
AT (1) ATE56942T1 (h)
AU (1) AU601167B2 (h)
CA (1) CA1266278A (h)
CS (1) CS259545B2 (h)
DD (1) DD263050A5 (h)
DE (1) DE3674570D1 (h)
DK (1) DK170770B1 (h)
EG (1) EG17770A (h)
ES (1) ES2018163T4 (h)
FI (1) FI90413C (h)
GB (1) GB8531071D0 (h)
GE (1) GEP19970812B (h)
GR (1) GR3001069T3 (h)
HU (1) HU201901B (h)
IE (1) IE59429B1 (h)
IL (1) IL80934A (h)
IN (1) IN163129B (h)
LU (1) LU90865I2 (h)
MX (1) MX4684A (h)
NL (1) NL300065I1 (h)
NO (2) NO165540C (h)
NZ (1) NZ218578A (h)
PH (1) PH22481A (h)
PL (1) PL149519B1 (h)
PT (1) PT83958B (h)
SU (1) SU1443796A3 (h)
UA (1) UA7206A1 (h)
YU (1) YU46033B (h)
ZA (1) ZA869078B (h)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
AU4542993A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
CA2359564A1 (en) * 1999-01-20 2000-07-27 Knoll Pharmaceutical Company Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
SK13372001A3 (sk) * 1999-03-19 2002-07-02 Knoll Gmbh Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
US6376553B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of pain
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6403650B1 (en) 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
AU3895400A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
IL145238A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Treatment of osteoarthritis
CA2367022A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sleep apnoea
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
PL375032A1 (en) * 2002-10-05 2005-11-14 Hanmi Pharm.Co, Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
EP1912968A1 (en) * 2005-08-04 2008-04-23 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
KR101036981B1 (ko) * 2006-02-23 2011-05-25 화이자 리미티드 멜라노코르틴 제４형 수용체 효능제 피페리디노일피롤리딘
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
RU2462451C2 (ru) * 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
DK2326638T5 (da) * 2008-08-06 2014-01-13 Pfizer Ltd Diazepin- og diazocan-forbindelser som mc4-agonister
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
AP3099A (en) 2009-11-02 2015-01-31 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2590969B1 (en) 2010-07-06 2014-10-15 AstraZeneca AB Therapeutic agents 976
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
CN105287604B (zh) 2010-11-08 2019-07-09 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
ATE56942T1 (de) 1990-10-15
CS930586A2 (en) 1988-02-15
NZ218578A (en) 1989-04-26
FI865030L (fi) 1987-06-18
LU90865I2 (fr) 2002-02-18
NO165540B (no) 1990-11-19
MX4684A (es) 1993-12-01
AU601167B2 (en) 1990-09-06
KR870005961A (ko) 1987-07-08
DK585786A (da) 1987-06-18
DK170770B1 (da) 1996-01-15
HU201901B (en) 1991-01-28
NO865093D0 (no) 1986-12-16
IE863102L (en) 1987-06-17
DD263050A5 (de) 1988-12-21
DK585786D0 (da) 1986-12-05
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
DE3674570D1 (de) 1990-10-31
US4929629A (en) 1990-05-29
UA7206A1 (uk) 1995-06-30
FI90413B (fi) 1993-10-29
GEP19970812B (en) 1997-02-10
FI865030A0 (fi) 1986-12-10
NL300065I1 (nl) 2001-12-01
HUT45964A (en) 1988-09-28
JPH0144176B2 (h) 1989-09-26
GB8531071D0 (en) 1986-01-29
ES2018163T4 (es) 2012-06-14
IN163129B (h) 1988-08-13
CN1016245B (zh) 1992-04-15
PL149519B1 (en) 1990-02-28
CN86108547A (zh) 1987-08-19
ZA869078B (en) 1987-07-29
GR3001069T3 (en) 1992-03-20
AU6644286A (en) 1987-06-18
YU205086A (en) 1987-12-31
EP0230742A1 (en) 1987-08-05
IE59429B1 (en) 1994-02-23
PL263020A1 (en) 1988-05-12
ES2018163B3 (es) 1991-04-01
CA1266278A (en) 1990-02-27
NO165540C (no) 1991-02-27
SU1443796A3 (ru) 1988-12-07
PT83958A (en) 1987-01-01
PT83958B (pt) 1989-05-12
JPS62155240A (ja) 1987-07-10
EP0230742B1 (en) 1990-09-26
CS259545B2 (en) 1988-10-14
IL80934A (en) 1990-07-26
NO2005022I1 (no) 2005-10-03
FI90413C (fi) 1994-02-10
NO865093L (no) 1987-06-18
PH22481A (en) 1988-09-12
EG17770A (en) 1991-03-30

Similar Documents

Publication Publication Date Title
YU46033B (sh) Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata
DK0711154T3 (da) Stabiliseret farmaceutisk præparat indeholdende bupropion
DE69032679D1 (de) Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
MY112915A (en) Multiple unit tableted dosage form 1
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
HUT41002A (en) Process for preparing anticonvulsives
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
IT9022507A0 (it) Procedimento per la preparazione di n-(26ammino63,5-dibromo-benzil)-trans-4-amminocicloesanolo3.
IT8619431A0 (it) Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono, procedimento per prepararlo e intermedio utile in detto procedimento.
IT1250747B (it) Composizioni farmaceutiche per la terapia della sindrome fibromialgica primaria
IT8421627A1 (it) Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo
SE9304065D0 (sv) New compound
IT1271398B (it) Composizioni farmaceutiche contenenti derivati polipeptidici del ferro per la terapia marziale